Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Assets (2022 - 2026)

Sagimet Biosciences' Assets history spans 5 years, with the latest figure at $107.8 million for Q1 2026.

  • Quarterly Assets fell 26.28% to $107.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $107.8 million through Mar 2026, down 26.28% year-over-year, with the annual reading at $116.5 million for FY2025, 27.32% down from the prior year.
  • Assets came in at $107.8 million for Q1 2026, down from $116.5 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $194.5 million in Q1 2024 to a low of $21.5 million in Q2 2023.
  • The 5-year median for Assets is $128.4 million (2025), against an average of $123.8 million.
  • Year-over-year, Assets surged 779.24% in 2024 and then fell 27.32% in 2025.
  • Sagimet Biosciences' Assets stood at $33.0 million in 2022, then soared by 192.81% to $96.7 million in 2023, then surged by 65.7% to $160.3 million in 2024, then dropped by 27.32% to $116.5 million in 2025, then fell by 7.49% to $107.8 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Assets are $107.8 million (Q1 2026), $116.5 million (Q4 2025), and $128.4 million (Q3 2025).